sastravi 50 mg/12,5 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 50 mg/12,5 mg/200 mg film - coated tablets
sastravi 75 mg/18,5 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 75 mg/18,5 mg/200 mg film - coated tablets
sastravi 100 mg/25 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 100 mg/25 mg/200 mg film - coated tablets
sastravi 125 mg/31,25 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 125 mg/31,25 mg/200 mg film - coated tablets
sastravi 150 mg/37,5 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 150 mg/37,5 mg/200 mg film - coated tablets
sastravi 175 mg/43,75 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 175 mg/43,75 mg/200 mg film - coated tablets
sastravi 200 mg/50 mg/200 mg film - coated tablets
actavis group ptc ehf. - l-dopa - 200 mg/50 mg/200 mg film - coated tablets
suvaxyn m. hyo - parasuis, suspension for injection for pigs
zoetis belgium s.a. - hyopneumoniae микоплазма, инактивированной , щам Р-5722-3; причинена от haemophilus parasuis серотипа 4, инактивированной, щам 2170b бактерията haemophilus parasuis серотипа 5, инактивированной, щам ia84-29755 - инжекционна суспензия - rp 1 – 1.9; rp 1 – 8.1; rp 1 – 3.4 - свине
suiseng coli
laboratorios hipra, s.a. - f4ab fimbrial adhesin of e. coli; f4ac fimbrial adhesin of e. coli; f5 fimbrial adhesin of e. coli; f6 fimbrial adhesin of e. coli; lt enterotoxoid of e. coli; toxoid clostridium perfringens, type c; toxoid clostridium novyi type b - инжекционна суспензия - ≥65% er60; ≥78% er70; ≥79% er50; ≥80% er25; ≥55% er70; ≥35% er25; ≥50% er120 - свине
suiseng suspension for injection for swine
laboratorios hipra, s.a. - Е. коли, энтеротоксигенных щамове (f4ab, f4ac, Ф5, Ф6, ЛТ); клостридии филтри, тип c, анатоксина; clostridium нов, анатоксина - инжекционна суспензия - ≥ 65 %; ≥ 78 %; ≥ 79 %; ≥ 80 %; ≥ 55 %; ≥ 35 %; ≥ 50 % - свине